|Ms. Nancy S. Lurker||Pres, CEO & Director||N/A||N/A||1957|
|Mr. Leonard S. Ross||VP of Fin., Chief Accounting Officer & Principal Financial Officer||N/A||N/A||1950|
|Ms. Deborah A. Jorn||Exec. VP of Corp. & Commercial Devel.||N/A||N/A||1958|
|Dr. Dario A. Paggiarino M.D.||VP & Chief Medical Officer||N/A||N/A||1957|
|Mr. Marty Nazzaro||Sr. VP of Operations||N/A||N/A||N/A|
pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. The company is also developing Durasert, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. It is also developing Durasert, which is in pre-clinical trials for the treatment of posterior segment uveitis; steroid implant for severe knee osteoarthritis; and TKI Insert, an injectable, bioerodible, sustained-release Durasert insert delivering a tyrosine kinase inhibitor for treatment of wet age-related macular degeneration. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Enigma Therapeutics Limited; and Nicox S.A. pSivida Corp. was founded in 1987 and is based in Watertown, Massachusetts.
pSivida Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.